Significantly superior tumor response rate

ABRAXANE significantly improved recTLRR vs paclitaxel injection in the ITT population

Tumor response for ITT population
aFrom Cochran-Mantel-Haenszel test stratified by first-line vs > first-line therapy.
ITT=intent-to-treat.

There was no statistically significant difference in overall survival between the two study arms

  • recTLRR was the prospectively defined, protocol-specific end point, based on independent radiologic assessment of tumor responses reconciled with investigator responses (which also included clinical information) for the first 6 cycles of therapy. The recTLRR was lower than the investigator-reported response rates, which are based on all cycles of therapy
Trial Design Data in relapsed and refractory patients

Significantly superior tumor response rate

ABRAXANE significantly improved recTLRR vs paclitaxel injection in the ITT population

Tumor response for ITT population
aFrom Cochran-Mantel-Haenszel test stratified by first-line vs > first-line therapy.
ITT=intent-to-treat.

There was no statistically significant difference in overall survival between the two study arms

  • recTLRR was the prospectively defined, protocol-specific end point, based on independent radiologic assessment of tumor responses reconciled with investigator responses (which also included clinical information) for the first 6 cycles of therapy. The recTLRR was lower than the investigator-reported response rates, which are based on all cycles of therapy
Trial Design Data in relapsed and refractory patients

INDICATION

ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

INDICATION

ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.